Its Russian label says it does not cause drug dependence or habituation, and its developers report no withdrawal or dependence in mice. We found no independent human study of dependence, and a 2021 US review called selank ‘poorly studied’.

Selank: Anxiety Evidence, Legal Status, Risks and Doses (2026)

Quick answers

What is it?: A lab-made chain of 7 amino acids. It adds a 3-amino-acid tail to tuftsin, a small peptide from the immune system, to make it resist breakdown¹. Russia sells it as nose drops for anxiety, without a prescription²⁵.
Does it work?: Not proven. In one Russian trial without a placebo, anxiety eased about as much as with medazepam, a Valium-like drug³. Added to a similar drug, it did not clearly help at 2 weeks⁴. No trial is registered in the main US database⁶.
Is it safe?: Unclear. The Russian label lists only allergic reactions and an unpleasant taste, and says it causes no dependence⁵. FDA says it may trigger immune reactions and that the agency lacks information on its safety in people⁷. A US review calls it poorly studied⁸.
Is it legal?: Not approved in the US, and US pharmacies may not make it⁷⁹. FDA put it on a do-not-compound list in 2023; it left that list only because its nomination was withdrawn⁷¹⁰. Russia approves it². Sport’s banned list does not name it¹¹¹².
What is in the vials?: Almost nothing is known. Finnrick, a testing service, lists a single selank test, from 3 August 2026, and it was incomplete¹³. Health Canada has seized unauthorized selank products¹⁴¹⁵.

What it is

Selank is a lab-made peptide, a chain of 7 amino acids: threonine, lysine, proline, arginine, proline, glycine and proline (Thr-Lys-Pro-Arg-Pro-Gly-Pro)¹¹⁶. The first four make up tuftsin, a small piece of the antibody protein IgG whose main known job is to spur immune cells to engulf germs¹. Russian scientists added a proline-glycine-proline tail, the same one used in semax, which they found best for stabilizing the molecule and making it resist enzymes¹. The Russian label describes it as a synthetic version of tuftsin, a peptide the body makes, and classes it as an anti-anxiety drug². How it works is not settled. Lab studies suggest it changes how GABA, the brain’s main calming messenger, binds to its receptors, the system that benzodiazepines such as diazepam (Valium) act on; in rats, a dose of selank or of GABA changed the activity of nerve-signaling genes in similar ways within an hour¹⁷¹⁸. It also blocks enzymes in human blood that break down enkephalins, the body’s own opioid-like peptides¹⁹²⁰. In rats given alcohol for 30 weeks, it prevented memory problems during withdrawal and blocked an alcohol-linked rise in BDNF, a nerve-support protein, in memory-related brain areas²¹. Blood enzymes cut it into smaller pieces²².

Tuftsin was isolated in 1970 by Najjar and Nishioka¹. In the early 1980s, the Russian researchers Valdman and Ashmarin proposed that this immune peptide also acts on the brain, and Russian scientists then built a longer-lasting version, named Selank¹. Russia’s Ministry of Health registered Selank 0.15% nasal drops in 2009¹. Vidal now lists a 2025 registration held by the company Peptogen, which replaced an earlier one, and the drops are sold without a prescription². Peptogen helped fund one of the main clinical trials⁴, and a 2013 English-language review of selank and semax was co-written by a semax developer¹. In the US, FDA placed ‘Selank Acetate (TP-7)’ in Category 2 of its compounding list in 2023 after it was nominated for pharmacy compounding; the nomination was later withdrawn⁷¹⁰.

Benefits: what the research shows

The human evidence is a handful of small Russian studies, published in Russian; we found no placebo-controlled anxiety trial³⁴⁴⁴. In 62 patients with generalized anxiety disorder or neurasthenia (nervous exhaustion), anxiety eased similarly in 30 given selank and 32 given medazepam, a Valium-like benzodiazepine; selank also eased fatigue and had a stimulating effect³. That abstract does not say whether patients were randomized or blinded, although PubMed indexes it as randomized³. A 2014 open randomized study gave 60 adults with anxiety disorders selank (2.7 mg a day) or phenazepam, another benzodiazepine (2 mg a day), for 14 days⁴⁴. At day 14, fewer people on selank met the response criteria (5 vs 7) and their anxiety scores fell less (26.3% vs 55%), but a week after both drugs stopped, selank had more responders (17 vs 9, p=0.037)⁴⁴. Its English summary reports ‘pronounced anxiolytic and mild nootropic effects’²⁴. A 2015 ‘open naturalistic prospective’ study randomly assigned 70 patients to phenazepam alone (2 mg a day) or with selank (2.7 mg a day) for 14 days⁴. At day 14, 40% responded with selank added versus 23% on phenazepam alone, a difference that was not statistically significant (p=0.14). All treatment then stopped, except in 20 patients of the selank group who took selank alone for a third week; 75% of them were responders at day 21, versus 30% in the phenazepam group, who by then were on no treatment. The paper does not say how those 20 were chosen. Adding selank reduced phenazepam’s side effects. The trial was funded in part by Peptogen, which holds the Russian registration²⁴. Other human data are smaller still. In patients with anxiety and fatigue, 14 days of selank shifted the balance of two types of immune signals, and in lab tests on blood cells from patients with depression it switched off the gene for IL-6, an inflammatory signal, although IL-6 levels in the culture rose²⁵. A placebo-controlled study in 52 healthy volunteers given selank, semax or placebo measured only brain-scan patterns at rest²⁶. The developers’ review cites Russian studies in which 2,700 µg a day quickly eased anxiety, including in patients over 50; we could not open them¹. No selank trial is registered on ClinicalTrials.gov: a search on 7 October 2026 returned 10 records, none mentioning selank⁶. Animal results depend on the strain: in mice, selank reduced anxiety only in BALB/c mice, a strain with higher baseline anxiety, and not in C57BL/6 mice, whether given in the nose or the abdomen¹²⁷. In rats it reduced anxiety-like behavior from day 2 of a 4-week course without changing weight, and one dose eased signs of morphine withdrawal by 39.6%, versus 49.3% for diazepam²⁸²⁹. A 2021 US review in the Journal of Clinical Pharmacology called phenibut and selank ‘poorly studied Russian drugs with GABAergic mechanisms that are inexplicably sold to US consumers as dietary supplements’⁸.

Key human studies

Study	Design	People	Dose and route	Result
Medvedev et al., Zh Nevrol Psikhiatr Im S S Korsakova 2015⁴PubMed · DOI	Open, randomized ‘naturalistic’ study in anxiety disorders: phenazepam alone versus phenazepam plus selank; no placebo or blinding; funded in part by the Russian registration holder	70	Selank 2.7 mg a day (route not stated) plus phenazepam 2 mg a day for 14 days (40 patients) versus phenazepam alone (30); 20 of the selank group then took selank alone to day 21	Responders at day 14: 40% with selank added versus 23% on phenazepam alone (p=0.14, not significant). At day 21, 75% of those who kept taking selank responded, versus 30% in the phenazepam group after stopping (p=0.0018). Adding selank reduced phenazepam’s side effects⁴.
Zozulia et al., Zh Nevrol Psikhiatr Im S S Korsakova 2008³PubMed	Comparison with medazepam (a benzodiazepine) in generalized anxiety disorder and neurasthenia; no placebo; randomization and blinding not stated in the abstract	62	Selank (dose and schedule not given in the abstract) versus medazepam	Anxiety eased similarly with selank (30 patients) and medazepam (32); selank also eased fatigue and had a stimulating effect. The blood half-life of leu-enkephalin, an opioid-like peptide, was short in patients and lengthened during selank treatment, mainly in generalized anxiety disorder³.
Medvedev et al., Zh Nevrol Psikhiatr Im S S Korsakova 2014⁴⁴PubMed	Open randomized ‘naturalistic’ study: selank versus phenazepam (a benzodiazepine) in anxiety disorders, adults aged 18 to 55; no placebo or blinding; supported by Peptogen, the Russian registration holder	60	Selank 2.7 mg a day (30 patients) versus phenazepam 2 mg a day (30) for 14 days; route not stated	At day 14, 5 on selank and 7 on phenazepam met the response criteria, and anxiety subscale scores fell 26.3% vs 55%. A week after both stopped, responders were 17 vs 9 (p=0.037). Dry nose was selank’s most marked side effect⁴⁴.
Panikratova et al., Doklady Biological Sciences 2020²⁶PubMed · DOI	Placebo-controlled brain-scan study (resting-state fMRI) in healthy volunteers comparing selank, semax and placebo	52	One dose of selank, semax or placebo, which the abstract calls an injection (FDA lists the semax dose as 1.2 mg in the nose); scans before and 5 and 20 minutes after	Selank and semax each changed connections between the right amygdala, a brain area involved in fear, and part of the right temporal lobe. The abstract reports no anxiety or memory outcomes²⁶.
Uchakina et al., Zh Nevrol Psikhiatr Im S S Korsakova 2008²⁵PubMed	Lab tests on blood cells plus immune-marker measurements in patients given selank; no control group described in the abstract	–	Selank for 14 days in patients (dose not given in the abstract); 0.1 µM in cell culture	In blood cells from patients with depression, but not from healthy people, selank switched off the gene for IL-6, an inflammatory signal, although IL-6 levels in the culture rose. Patients with generalized anxiety disorder or neurasthenia given selank for 14 days showed shifts in the balance of Th1 and Th2 immune signals²⁵.

Doses studied

Doses below are what studies used or what a label says. They are not advice, and gray-market products may not contain what their label says.

In human studies

Russian label (nasal drops, 1.5 mg per mL): 2 drops in each nostril 3 times a day for 14 days, repeatable after 1 to 3 weeks on a doctor’s advice; the label does not state the amount per drop⁵. Trials: 2.7 mg a day for 14 days, compared with phenazepam⁴⁴ or added to it and then given alone to day 21⁴; neither paper states the route. The developers’ review describes 2,700 µg a day in anxiety studies, including a 14-day course in patients over 50¹. We found no human study of selank injected under the skin.

In animal studies

As reported. Rats: 0.3 mg/kg into the abdomen daily for 4 weeks (anxiety)²⁸, daily for 7 days (alcohol withdrawal and memory)²¹, or once (morphine withdrawal)²⁹; 300 µg/kg in a gene-activity study¹⁸. Mice: 300 µg/kg a day for 5 days, in the nose or the abdomen²⁷; 200 to 3,000 µg/kg in anxiety tests¹.

What users report Anecdotal · not validated · not a recommendation

A peptide dosing site (updated 26 September 2026) lists 300 µg per dose as a nasal spray, 3 times a day (900 µg a day). It calls this ‘research reference only’, a translation of the Russian drop schedule, and says a custom solution and pump ‘are not equivalent to the registered preserved formulation’³⁹.

Half-life: Minutes¹²The Russian label says that after a nasal dose selank appears in the blood within 30 seconds, with 92.8% absolute bioavailability, and that blood levels fall steadily over 5 to 5.5 minutes; it does not say which species these figures come from². The developers’ review gives a half-life of about 2 minutes in lab tests¹. Blood enzymes cut it into smaller pieces, mainly TKPRP, TKP, RP and GP²². In rats, nasal dosing delivered the most to the brain of the routes compared, and the peptide built up in stomach tissue whatever the route³⁸.
Routes: Nasal drops (Russia’s 0.15% product; the form in the Russian studies that state a route)
Nasal spray (sold online and by US clinics, alone or blended with semax; no human data found on these products)
Subcutaneous injection, under the skin (sold online; no human data found)
Intraperitoneal injection, into the abdomen (animal studies only)

Every dose studied for Selank, with sources →

Legal status

United States: Not approved by FDA for any use; federal prosecutors have described it as an unapproved new drug³⁰. A Kentucky compounding pharmacy pleaded guilty to distributing unapproved new drugs from 25 October 2018 to 1 April 2020; its plea agreement says these included selank and semax. On 24 February 2021 it was sentenced to 3 years of probation and forfeited $1,788,906.82, its 2019 sales of these products³⁰. In a 10 November 2021 warning letter to an Indianapolis firm, FDA noted that selank, semax and several other peptides ‘were not nominated for inclusion on the 503A bulks list’ at that time³². A 2021 review said selank was ‘inexplicably sold to US consumers as dietary supplements’⁸. No selank trial is registered on ClinicalTrials.gov (searched 7 October 2026)⁶.
US pharmacies: Section 503A of federal drug law covers compounding by pharmacies for individual patients. FDA added ‘Selank Acetate (TP-7)’ to Category 2 of its interim 503A bulks list, substances that raise significant safety concerns, in its 29 September 2023 update¹⁰. The nomination was later withdrawn, and FDA’s safety-risk page now lists selank acetate under ‘Bulk drug substances nominated but withdrawn’, substances ‘previously in category 2’ whose nominators withdrew them⁷. That page says selank acetate ‘may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities’ (unwanted immune reactions from clumping and impurities), and that ‘FDA lacks important information regarding any safety issues raised by selank acetate administered to humans’⁷. Selank is in no category of the list updated 14 May 2026, so US pharmacies cannot lawfully compound it under section 503A; being out of Category 2 does not make a substance eligible⁹³³. Unlike semax, selank is not among the 12 peptides that a law firm lists as leaving Category 2 after FDA’s 15 April 2026 notice³³. It was not on the agenda of the July 2026 advisory committee meeting³⁴, and it is not among the 5 substances FDA lists for a later meeting before the end of February 2027⁴⁵. We could not find who nominated it or when the nomination was withdrawn.
Other countries: Russia: Vidal and RLS, two Russian drug references, list Selank 0.15% nasal drops (registration ЛП-№(010951)-(РГ-RU), dated 15 July 2025, replacing ЛСР-003338/09), held by Peptogen and sold without a prescription²⁵. Its uses include anxiety states, panic attacks, neurasthenia, fatigue (asthenia), mood instability, sleep problems and adjustment disorders². The developers’ review says Russia’s Ministry of Health first registered it in 2009¹. The official Russian register (GRLS) could not be opened. Canada: Health Canada lists selank among unauthorized injectable peptides seized from a Calgary clinic (1 April 2025) and seized from and sold by an online seller (1 August 2025); it says injectable peptides are regulated as prescription drugs in Canada and that ‘For Research Use Only’ labels do not make products legal¹⁴¹⁵³⁵. Belgium: Sciensano, Belgium’s public health institute, identified selank and semax in two suspicious preparations encountered at the end of 2017 and 2018³⁶. Australia: selank is not named in the Poisons Standard in force from 1 October 2026³¹. UK and EU: not verified.
Sport: Selank is not named on WADA’s (World Anti-Doping Agency) 2026 Prohibited List or on the 2027 List, which takes effect on 1 January 2027, and by our reading no named class such as S2 (peptide hormones, growth factors, related substances and mimetics) covers it¹¹¹². Class S0 bans substances not covered elsewhere ‘with no current approval by any governmental regulatory health authority for human therapeutic use’; the 2027 List adds ‘peptides’ to its examples¹¹¹². Russia has approved selank as non-prescription nose drops, registered as ЛП-№(010951)-(РГ-RU)². By our reading, that current approval puts selank outside S0, so it is likely allowed. This is not a WADA ruling, and it rests on a Russian approval, so athletes should not rely on it. WADA’s note on the 2027 List says that even if a peptide is not named, ‘utmost caution should be taken as it may still be prohibited and may be harmful to health’³⁷.

Selank in the legal tracker →

Quality and the gray market

What testing finds

Finnrick, an independent testing service, lists a single selank test, from one seller on 3 August 2026, and it was incomplete¹³. Incomplete tests do not count toward its pass rate, so there are no usable purity data⁴⁰. FDA says selank acetate may carry risk from clumping (aggregation) and peptide-related impurities⁷. On one US seller’s site (accessed 5 October 2026), the selank page listed the correct formula (C33H57N11O9) and weight (751.88)⁴¹. In Belgium, Sciensano identified selank and semax in two suspicious preparations encountered at the end of 2017 and 2018³⁶. No FDA sampling or recall of selank was found.

How it is sold

FDA’s 2026 review of semax found a US website selling a ‘50:50’ semax and selank blend as a 2.5 mg/mL injection and a 1.25 mg/mL nasal spray⁴². Online sellers offer research-labeled vials: one US seller listed selank 10 mg at $52 and ‘N-Acetyl Selank’ 10 mg at $71, ‘sold for laboratory research use only’ (accessed 5 October 2026)²³⁴¹. A 2021 review said selank was being sold to US consumers as a dietary supplement⁸. Demand signals are thin: Finnrick had logged a single selank test by 3 August 2026¹³. Health Canada has seized selank from a Calgary clinic and from an online seller¹⁴¹⁵, and a Kentucky pharmacy whose plea agreement names selank among the unapproved drugs it distributed was sentenced in 2021³⁰.

Side effects and risks

Little safety data: the human studies were small and short, and FDA says it ‘lacks important information regarding any safety issues raised by selank acetate administered to humans’⁷.
Unwanted immune reactions: FDA says it may pose a risk of immunogenicity from clumping and impurities⁷. The Russian label lists allergic reactions, including delayed ones, and warns that its preservative, methylparaben, may cause allergy⁵.
Effects on other calming drugs: selank appears to act on the GABA system, the target of benzodiazepines, and in stressed rats it changed and strengthened diazepam’s anti-anxiety effect¹⁷⁴³. The label reports no established interaction with haloperidol, barbiturates or alcohol, but a US review calls selank poorly studied⁵⁸.
Dependence claims are untested independently: the Russian label says it does not cause drug dependence or habituation, and its developers report no withdrawal or dependence in mice, but no independent study has checked this¹⁵.
Pregnancy and age: the label rules out use in pregnancy, breastfeeding and under age 18².
Unknown contents: Finnrick has no completed selank test, and Health Canada warns that unauthorized injectable peptides may carry risks such as infection, allergic reactions and contaminants¹³¹⁵.
Legal and sport risk: Health Canada has seized selank products, and a US pharmacy whose plea agreement names selank among the unapproved drugs it distributed was sentenced in 2021¹⁵³⁰. WADA urges ‘utmost caution’ with unnamed peptides³⁷.

Questions people ask

Is Selank FDA approved?

No. FDA has not approved selank for any use, and federal prosecutors have described it as an unapproved new drug³⁰. In Russia, Selank 0.15% nose drops are registered and sold without a prescription²⁵.

Is Selank a benzodiazepine?

No. Selank is a peptide of 7 amino acids, not a benzodiazepine, but lab studies suggest it acts on the same GABA calming system¹¹⁷. In one small Russian trial, its anti-anxiety effect was similar to that of the benzodiazepine medazepam³.

Selank vs semax: what’s the difference?

Both are Russian nasal peptides of 7 amino acids that end in the same Pro-Gly-Pro tail¹. Selank starts with tuftsin, an immune peptide, and is sold for anxiety; semax starts with a piece of ACTH, a stress hormone, and is sold for stroke and memory¹. FDA found a ‘50:50’ blend of the two marketed in the US⁴².

Is Selank legal in the US?

It is not an approved drug, and US pharmacies may not compound it⁷⁹. A Kentucky pharmacy whose plea agreement names selank among the unapproved drugs it distributed was sentenced in 2021³⁰.

Is Selank addictive?

Its Russian label says it does not cause drug dependence or habituation, and its developers report no withdrawal or dependence in mice¹⁵. We found no independent human study of dependence, and a 2021 US review called selank ‘poorly studied’⁸.

What is N-acetyl selank?

A modified form sold online, with an acetyl group capping the start of the chain²³. It is not the Russian medicine, and we found no human study of it.

What is still unknown

Who nominated selank for US compounding, and when was the nomination withdrawn? FDA’s pages show only that it was added to Category 2 in 2023 and is now ‘nominated but withdrawn’.
Is the Russian registration current in the official State Register of Medicines (GRLS)? GRLS could not be opened; Vidal and RLS list it.
How much selank is in each drop of the Russian product? The label gives the strength (1.5 mg per mL) but not the drop size, so its schedule cannot be compared directly with the 2.7 mg a day used in trials.
Were the 2008 and 2014 comparisons with benzodiazepines randomized or blinded? Their abstracts do not say, and the full texts could not be opened.
The Russian studies of 2,700 µg a day cited in the developers’ review (by Neznamov and by Teleshova) could not be opened.
Does selank cause dependence or withdrawal in people? Only label and developer claims were found.
Is selank approved anywhere besides Russia? Not verified.
What is its legal status in the UK and EU? Not verified.
What did the vials contain? Finnrick’s only test was incomplete.
How large is US demand? Reddit and Google Trends could not be checked for this article.

Sources

1A New Generation of Drugs: Synthetic Peptides Based on Natural Regulatory Peptides Neuroscience & Medicine (Scientific Research Publishing), Dec 2013. scirp.org
2Селанк (Selank) 0.15% nasal drops: instructions for use Vidal Russia drug reference, 22 Oct 2018. vidal.ru
3Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia (in Russian) Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2008. pubmed.ncbi.nlm.nih.gov
4Optimization of the treatment of anxiety disorders with selank (in Russian) Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2015. pubmed.ncbi.nlm.nih.gov
5Селанк (Selank) 0.15% nasal drops: instructions, doses, side effects RLS (Register of Medicinal Products of Russia), 15 Jul 2025. rlsnet.ru
6ClinicalTrials.gov search for ‘selank’ (10 records, none mentioning selank) ClinicalTrials.gov, accessed 7 Oct 2026. clinicaltrials.gov
7Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks U.S. Food and Drug Administration, 22 Apr 2026. fda.gov
8Sedative-Hypnotic Agents That Impact Gamma-Aminobutyric Acid Receptors: Focus on Flunitrazepam, Gamma-Hydroxybutyric Acid, Phenibut, and Selank Journal of Clinical Pharmacology, Aug 2021. pubmed.ncbi.nlm.nih.gov
9Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (categories list) U.S. Food and Drug Administration, 14 May 2026. fda.gov
10Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (categories list updated 29 September 2023) U.S. Food and Drug Administration (copy hosted by the Alliance for Pharmacy Compounding), 29 Sep 2023. join.a4pc.org
11World Anti-Doping Code International Standard: Prohibited List 2026 World Anti-Doping Agency, 24 Sep 2025. wada-ama.org
12World Anti-Doping Code International Standard: Prohibited List 2027 World Anti-Doping Agency, 21 Sep 2026. wada-ama.org
13Selank Safety Testing Results & Vendor Ratings Finnrick, 3 Aug 2026. finnrick.com
14Unauthorized injectable peptide drugs seized from Optimum Wellness Centre in Calgary, Alberta may pose serious health risks (RA-77218) Health Canada, 1 Apr 2025. recalls-rappels.canada.ca
15Unauthorized injectable peptide drugs seized and sold by Canada Peptide may pose serious health risks (RA-77807) Health Canada, 1 Aug 2025. recalls-rappels.canada.ca
16Selank (PubChem CID 11765600) PubChem, National Center for Biotechnology Information, accessed 7 Oct 2026. pubchem.ncbi.nlm.nih.gov
17Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity Protein and Peptide Letters, 2018. pubmed.ncbi.nlm.nih.gov
18Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission Frontiers in Pharmacology, 2016. pubmed.ncbi.nlm.nih.gov
19The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity Bulletin of Experimental Biology and Medicine, Apr 2001. pubmed.ncbi.nlm.nih.gov
20Semax and selank inhibit the enkephalin-degrading enzymes from human serum (in Russian) Bioorganicheskaia Khimiia, May 2001. pubmed.ncbi.nlm.nih.gov
21Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats Bulletin of Experimental Biology and Medicine, Sep 2019. pubmed.ncbi.nlm.nih.gov
22Evenly tritium-labeled peptides and their in vivo and in vitro biodegradation (in Russian) Bioorganicheskaia Khimiia, Mar 2006. pubmed.ncbi.nlm.nih.gov
23Research Peptides for Sale + Blends (catalog listing N-Acetyl Selank, 10MG) Core Peptides (vendor), accessed 5 Oct 2026. corepeptides.com (seller page, deliberately not linked)
24A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders (in Russian) Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2014. pubmed.ncbi.nlm.nih.gov
25Immunomodulatory effects of selank in patients with anxiety-asthenic disorders (in Russian) Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2008. pubmed.ncbi.nlm.nih.gov
26Functional Connectomic Approach to Studying Selank and Semax Effects Doklady Biological Sciences, Jan 2020. pubmed.ncbi.nlm.nih.gov
27Comparison of pharmacological effects of heptapeptide selank after intranasal and intraperitoneal administration to BALB/c and C57BL/6 mice (in Russian) Eksperimental’naia i Klinicheskaia Farmakologiia, 2016. pubmed.ncbi.nlm.nih.gov
28Influence of long-term treatment with tuftsin analogue TP-7 on the anxiety-phobic states and body weight Pharmacological Reports, Jul 2006. pubmed.ncbi.nlm.nih.gov
29Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats Bulletin of Experimental Biology and Medicine, Oct 2022. pubmed.ncbi.nlm.nih.gov
30Nicholasville Compounding Pharmacy and Its Owner Sentenced for Unlawful Distribution of Prescription Drugs U.S. Attorney’s Office, Eastern District of Kentucky, 24 Feb 2021. justice.gov
31Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327) Federal Register of Legislation, Australian Government, 28 Sep 2026. legislation.gov.au
32Warning letter to Advanced Nutriceuticals, LLC dba The Guyer Institute of Molecular Medicine (MARCS-CMS 615908) U.S. Food and Drug Administration, 10 Nov 2021. fda.gov
33FDA to Remove 12 Popular Peptides from the Category 2 ‘Do Not Compound’ List Frier Levitt, 16 Apr 2026. frierlevitt.com
34July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee U.S. Food and Drug Administration, 6 Aug 2026. fda.gov
35Think twice before injecting peptides bought online: unauthorized products can seriously harm you (RA-81874) Health Canada, 9 Apr 2026. recalls-rappels.canada.ca
36The occurrence of putative cognitive enhancing research peptides in seized pharmaceutical preparations: An incentive for controlling agencies to prepare for future encounters of the kind Drug Testing and Analysis, Mar 2020. pubmed.ncbi.nlm.nih.gov
37Summary of Major Modifications and Explanatory Notes: 2027 Prohibited List World Anti-Doping Agency, 21 Sep 2026. wada-ama.org
38A comparative analysis of distribution of glyprolines administered by various routes (in Russian) Bioorganicheskaia Khimiia, Jul 2008. pubmed.ncbi.nlm.nih.gov
39Selank Dosage: 10 mg Nasal Research Guide PeptideDosages, 26 Sep 2026. peptidedosages.com
40Methodology Finnrick, accessed 5 Oct 2026. finnrick.com
41Selank Peptide for Sale (10mg) Core Peptides (vendor), accessed 5 Oct 2026. corepeptides.com (seller page, deliberately not linked)
42FDA Evaluation of Semax-Related Bulk Drug Substances (Semax (Free Base) and Semax Acetate), PCAC briefing document U.S. Food and Drug Administration, 11 May 2026. fda.gov
43Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats Behavioural Neurology, 2017. pubmed.ncbi.nlm.nih.gov
44Сравнение анксиолитического эффекта и переносимости селанка и феназепама при терапии тревожных расстройств (full text, in Russian) Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova (Media Sphera), 2014. mediasphera.ru
45Meeting of the Pharmacy Compounding Advisory Committee (to be held before the end of February 2027) U.S. Food and Drug Administration, 15 Apr 2026. fda.gov

Not medical advice. This page reports what studies and regulators say; it does not recommend using any product. How we grade evidence · Report an error.